BridgeBio Pharma
BBIO
116 hedge funds and large institutions have $3.82B invested in BridgeBio Pharma in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 43 increasing their positions, 23 reducing their positions, and 10 closing their positions.
3,325% more call options, than puts
Call options by funds: $25.4M | Put options by funds: $743K
220% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 10
87% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 23
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
22% more funds holding
Funds holding: 95 → 116 (+21)
17% more capital invested
Capital invested by funds: $3.28B → $3.82B (+$548M)
5.36% more ownership
Funds ownership: 91.29% → 96.65% (+5.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$104M |
| 2 |
State Street
Boston,
Massachusetts
|
+$44.9M |
| 3 |
Citigroup
New York
|
+$21.1M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$16.4M |
| 5 |
BlackRock
New York
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
-$72.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.9M |
| 3 |
AIG
American International Group
New York
|
-$9.09M |
| 4 |
Millennium Management
New York
|
-$5.99M |
| 5 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$4.68M |
BBIO Hedge Fund Activity: Q2 2020 in Review
116 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2020, worth a combined $3.82B — up 17% from $3.28B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new BBIO positions and 10 closed out — a net gain of 22 holders — while 43 added to existing stakes and 23 trimmed.
The largest buyer was Vanguard Group, adding an estimated $104M. The largest seller was Kohlberg Kravis Roberts & Co, cutting an estimated $72.8M.
- 116 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2020, up from 95 in Q1 2020.
- Funds reported $3.82B of BridgeBio Pharma stock for Q2 2020, up 17% quarter-over-quarter.
- 32 funds opened new BridgeBio Pharma positions in Q2 2020 and 10 closed out, a net change of +22 holders.
- The largest BridgeBio Pharma buyer in Q2 2020 was Vanguard Group, an estimated $104M added.
- The largest BridgeBio Pharma seller in Q2 2020 was Kohlberg Kravis Roberts & Co, an estimated $72.8M sold.
Based on aggregated 13F filings for Q2 2020.